---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022283"
form_type: "8-K"
ticker: "SCNX"
cik: "0001382574"
company_name: "Scienture Holdings, Inc."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T17:48:24.779590+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TRxADE enters binding LOI to acquire Superlatus; 3.84M shares valued at $58.61/share

## Summary
- Superlatus shareholders to receive 3,839,176 MEDS shares: 19.99% common stock plus non-voting preferred.
- Transaction valued at $58.61 per share; combined targets must be valued at least $225M.
- Definitive merger agreement subject to due diligence, audited financials, and Nasdaq approval.
- Superlatus must first acquire Sapentia and Prestige Farms within 45 days of LOI.
- LOI may be terminated unilaterally by TRxADE or after 60-day due diligence period.

## SEC filing metadata
- accession: 0001493152-23-022283
- form_type: 8-K
- ticker: SCNX
- cik: 0001382574
- company_name: Scienture Holdings, Inc.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382574/000149315223022283/0001493152-23-022283-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382574/000149315223022283/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022283
- JSON: https://secwatch.observer/filing/0001493152-23-022283.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022283.txt

## Key facts
- Material Agreements
  Scienture Holdings, Inc. amended Amendment to Acquisition Letter with Superlatus, Inc. valued at Amendment to correct the number of shares to be received by Superlatus shareholders upon closing of (effective 2023-06-23).
  - Action: amendment
  - Agreement: merger
  - Counterparty: Superlatus, Inc.
  - Value: Amendment to correct the number of shares to be received by Superlatus shareholders upon closing of
  - Effective: 2023-06-23
  source text: On June 23, 2023, the Company and Superlatus entered into an amendment (the “Amendment to Acquisition Letter”) to the LOI to correct the number of shares to be received by Superlatus shareholders upon closing of the Merger.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382574/000149315223022283/0001493152-23-022283-index.htm
- Material Agreements
  Scienture Holdings, Inc. entered into Binding Letter of Intent for Merger with Superlatus, Inc. valued at 3,839,176 shares of the Company, valued at $58.61 per share, comprised of common stock (19.99% of to (effective 2023-06-22).
  - Action: entry
  - Agreement: merger
  - Counterparty: Superlatus, Inc.
  - Value: 3,839,176 shares of the Company, valued at $58.61 per share, comprised of common stock (19.99% of to
  - Effective: 2023-06-22
  source text: On June 22, 2023, TRxADE HEALTH, Inc. (the “Company”) entered into a binding letter of intent (“LOI”) for a merger (the “Merger”) with Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities (“Superlatus”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382574/000149315223022283/0001493152-23-022283-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.